The Hyderabad-based pharma major Bharat Biotech’s Covaxin has got the emergency use approval for children aged 2 to 18 years from the Drugs Controller General of India (DCGA).
The Subject Expert Committee on COVID-19 approved the emergency use in the children.
The expert panel said in a statement, “After detailed deliberation, the committee recommended for grant of market authorisation of the vaccine for the age group of 2 to 18 years for restricted use in an emergency.”
Bharat Biotech had submitted the trial data of phases 2 and 3 of Covaxin on children at the beginning of this month to the apex body — DCGI at the start of this month. The vaccine will be administered in two doses with 20 days of interval.
However, Bharat Biotech must submit safety data with due analysis every 15 days for the first two months and monthly thereafter.
Remarkably, the global health body World Health Organisation has not granted the emergency use authorisation to Covaxin. The World Health Organisation said last week that it would carry out the risk and benefit assessment next week with experts and take a final decision on the much-awaited EUL to Covaxin.
The WHO said in the last meeting, “WHO & an independent group of experts are scheduled to meet next week to carry out the risk/benefit assessment and come to a final decision whether to grant Emergency Use Listing to Covaxin”.
Meanwhile, India continues to show declining trends in the daily trajectory of COVID caseloads. India on Tuesday reported 14,313 fresh COVID cases in the last 24 hours, the lowest recorded cases in the 224 days. Total 181 deaths have also been reported in the same period, pushing the death toll to 4,50,963, the Union Health Ministry said.
The Active Caseload is presently 2,14,900, which is the lowest in 212 days. The active COVID cases presently constitute 0.63 per cent of the country’s total positive cases.
The above article has been published from a wire agency with minimal modifications to the headline and text.